Clinical Trial Update: 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 211At-BC8-B10 given before donor stem cell transplant in high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• 211At-BC8-B10 (Astatine-211 labeled BC8-B10 antibody)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: RECRUITING